



Notice Regarding Completion of PMDA Consultation on the Clinical Trial Plan for iPS-Derived Glial Progenitor Cells (iGRP)

October 26, 2026

REPROCELL Incorporated (the "Company") announces that it has completed a face-to-face consultation with the Pharmaceuticals and Medical Devices Agency (PMDA) regarding the clinical trial plan for its iPS-derived glial progenitor cells (iGRP) for the treatment of amyotrophic lateral sclerosis (ALS).

The Company is developing this product as a novel treatment for ALS using glial progenitor cells generated from induced pluripotent stem (iPS) cells.

Based on the discussions held during the consultation, the Company has finalized the key design elements of the clinical trial protocol.

The clinical trial is planned to be conducted at Nagoya University. The Company will proceed with the necessary preparations for submitting a Clinical Trial Notification.

The impact of this matter on the Company's consolidated financial results for the current fiscal year is expected to be minimal. The Company will promptly disclose any additional information that requires disclosure.

Glossary

1. iPS-Derived Glial Progenitor Cells (iGRP)

iGRP are progenitor cells generated through the differentiation of iPS cells. They have the ability to differentiate into glial cells, including astrocytes and oligodendrocytes. The Company is developing iGRP as a regenerative medicine product aimed at protecting motor neurons affected by ALS through the functions of glial cells, which support neurons.

2. Amyotrophic Lateral Sclerosis (ALS)

ALS is a neurodegenerative disease characterized by the progressive degeneration of motor neurons, which control muscle movement. The disease causes muscle weakness and atrophy in the limbs and eventually affects functions such as swallowing and breathing.

ALS is designated as an intractable disease (Designation No. 2) by Japan's Ministry of Health, Labour and Welfare (MHLW). The number of patients in Japan is estimated at approximately 10,000. As of the end of fiscal year 2024, 9,768 individuals held recipient certificates for specified medical expenses under the designated intractable diseases program.

(Source: Ministry of Health, Labour and Welfare, Report on Public Health Administration and Services, FY2024)